Influence of Mutation Type and Location on Phenotype in 123 Patients with Rett Syndrome

Abstract

Rett syndrome (RTT) is a neurodevelopmental disorder that almost exclusively affects girls. It is caused by mutations in the MECP2 gene that encodes the methyl-CpG-binding protein 2 (MeCP2). In this study we correlated mutation type and location with the severity of the phenotype in 123 girls with RTT. The ability to sit, walk, speak, hand function, head growth, occurrence of epilepsy and a combined severity score were assessed in all girls at 5 years of age and then statistically correlated with the results of the molecular genetic tests. We found that patients who carry either missense mutations or deletions located within the hotspot for deletions, an area between the base pairs (bp) 1030 and 1207 of the MECP2 gene, present with a milder phenotype than other patients. We correlated the location of the mutations with the phenotype and found that all mutations that lead to either a complete or partial truncation of the region coding for the nuclear localisation signal (NLS) are associated with a more severe phenotype than other truncating mutations (p = 0.001). We did not find a significant difference between the patients with mutations in the methyl-CpG-binding domain (MBD) and those with mutations in the transcriptional repression domain (TRD). We conclude that mutation type and location correlate with the phenotype in Rett syndrome. All mutations that impair the nuclear localisation signal (NLS) are associated with more severe phenotypes.

Key words

Rett Syndrome - Genotype and Phenotype Correlation - RTT Severity Score

References

• 1 Amano K, Nomura Y, Segawa M. et al . Mutational analysis of the MECP2 gene in Japanese patients with Rett syndrome.  J Hum Genet. 2000;  45 231-236
• 2 Amir R E, Van den Veyver I B, Wan M. et al . Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl- CpG-binding protein 2.  Nat Genet. 1999;  23 185-188
• 3 Amir R E, Van den Veyver I B, Schultz R. et al . Influence of mutation type and X chromosome inactivation on Rett syndrome phenotypes.  Ann Neurol. 2000;  47 670-679
• 4 Anvret M, Wahlstrom J. Rett syndrome: random X chromosome inactivation.  Clin Genet. 1994;  45 274-275
• 5 Auranen M, Vanhala R, Vosman M. et al . MECP2 gene analysis in classical Rett syndrome and in patients with Rett-like features.  Neurology. 2001;  56 611-617
• 6 Bienvenu T, Carrie A, de Roux N. et al . MECP2 mutations account for most cases of typical forms of Rett syndrome.  Hum Mol Genet. 2000;  9 1377-1384
• 7 Bourdon V, Philippe C, Labrune O. et al . A detailed analysis of the MECP2 gene: prevalence of recurrent mutations and gross DNA rearrangements in Rett syndrome patients.  Hum Genet. 2001;  108 43-50
• 8 Buyse I M, Fang P, Hoon K T. et al . Diagnostic testing for Rett syndrome by DHPLC and direct sequencing analysis of the MECP2 gene: identification of several novel mutations and polymorphisms.  Am J Hum Genet. 2000;  67 1428-1436
• 9 Camus P, Abbadi N, Perrier M C. et al . X chromosome inactivation in 30 girls with Rett syndrome: analysis using the probe.  Hum Genet. 1996;  97 247-250
• 10 Cheadle J P, Gill H, Fleming N. et al . Long-read sequence analysis of the MECP2 gene in Rett syndrome patients: correlation of disease severity with mutation type and location.  Hum Mol Genet. 2000;  9 1119-1129
• 11 Chen R Z, Akbarian S, Tudor M. et al . Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice.  Nat Genet. 2001;  27 327-331
• 12 D'Esposito M, Quaderi N A, Ciccodicola A. et al . Isolation, physical mapping, and Northern analysis of the X-linked human gene encoding methyl CpG-binding protein, MECP2.  Mamm Genome. 1996;  7 533-535
• 13 Guy J, Hendrich B, Holmes M. et al . A mouse MeCP2-null mutation causes neurological symptoms that mimic Rett syndrome.  Nat Genet. 2001;  27 322-326
• 14 Hagberg B. Rett's syndrome: prevalence and impact on progressive mental retardation in girls.  Acta Pediatr Scand. 1985;  74 405-408
• 15 Hagberg B A. Rett syndrome: clinical peculiarities, diagnostic approach, and possible cause.  Pediatr Neurol. 1985;  5 75-83
• 16 Hagberg G, Stenbom Y, Witt Engerstrom. Head growth in Rett syndrome.  Acta Paediatr. 2000;  89 198-202
• 17 Hampson K, Woods C G, Latif F. et al . Mutations in the MECP2 gene in a cohort of girls with Rett syndrome.  J Med Genet. 2000;  37 610-612
• 18 Huppke P, Laccone F, Kramer N. et al . Rett syndrome: analysis of MECP2 and clinical characterization of 31 patients.  Hum Mol Genet. 2000;  9 1369-1375
• 19 Jones P L, Veenstra G J, Wade P A. et al . Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription.  Nat Genet. 1998;  19 187-191
• 20 Kormann-Bortolotto M H, Woods C G, Green S H. et al . X-inactivation in girls with Rett syndrome.  Clin Genet. 1992;  42 296-301
• 21 Laccone F, Huppke P, Hanefeld F. et al . Mutation spectrum in patients with Rett syndrome in the German population: Evidence of hot spot regions.  Hum Mutat. 2001;  17 183-90
• 22 Lewis J D, Meehan R R, Henzel W J. et al . Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA.  Cell. 1992;  69 905-914
• 23 Meehan R R, Lewis J D, Bird A P. Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA.  Nucleic Acids Res. 1992;  20 5085-5092
• 24 Migeon B R, Dunn M A, Thomas G. et al . Studies of X inactivation and isodisomy in twins provide further evidence that the X chromosome is not involved in Rett syndrome.  Am J Hum Genet. 1995;  56 647-653
• 25 Nan X, Campoy F J, Bird A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin.  Cell. 1997;  88 471-481
• 26 Nan X, Meehan R R, Bird A. Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2.  Nucleic Acids Res. 1993;  21 4886-4892
• 27 Nan X, Tate P, Li E. et al . DNA methylation specifies chromosomal localization of MeCP2.  Mol Cell Biol. 1996;  16 414-421
• 28 Ng H H, Zhang Y, Hendrich B. et al . MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex.  Nat Genet. 1999;  23 58-61
• 29 Nielsen J B, Henriksen K F, Hansen C. et al . MECP2 mutations in Danish patients with Rett syndrome: High frequency of mutations but no consistent correlations with clinical severity or with the X chromosome inactivation pattern.  Eur J Hum Genet. 2001;  9 178-184
• 30 Steffenburg U, Hagberg G, Hagberg B. Epilepsy in a representative series of Rett syndrome.  Acta Paediatr. 2001;  90 34-39
• 31 Vacca M, Filippini F, Budillon A. et al . Mutation analysis of the MECP2 gene in British and Italian Rett syndrome females.  J Mol Med. 2001;  78 648-655
• 32 Villard L, Kpebe A, Cardoso A K. et al . Two affected boys in a Rett syndrome family: clinical and molecular findings.  Neurology. 2000;  55 1188-1193
• 33 Wade P A, Jones P L, Vermaak D. et al . Histone deacetylase directs the dominant silencing of transcription in chromatin: association with MeCP2 and the Mi-2 chromodomain SWI/SNF ATPase.  Cold Spring Harb Symp Quant Biol. 1998;  63 435-445
• 34 Wade P A, Gegonne A, Jones P L. et al . Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation.  Nat Genet. 1999;  23 62-66
• 35 Wan M, Lee S S, Zhang X. et al . Rett syndrome and beyond: recurrent spontaneous and familial MECP2 mutations at CpG hotspots.  Am J Hum Genet. 1999;  65 1520-1529
• 36 Webb T, Watkiss E. A comparative study of X-inactivation in Rett syndrome probands and control subjects.  Clin Genet. 1996;  49 189-195
• 37 Xiang F, Buervenich S, Nicolao P. et al . Mutation screening in Rett syndrome patients.  J Med Genet. 2000;  37 250-255
• 38 Zoghbi H Y, Percy A K, Schultz R J. et al . Patterns of X chromosome inactivation in the Rett syndrome.  Brain Dev. 1990;  12 131-135